Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5289729
Max Phase: Preclinical
Molecular Formula: C39H52ClN3O17
Molecular Weight: 486.06
Associated Items:
ID: ALA5289729
Max Phase: Preclinical
Molecular Formula: C39H52ClN3O17
Molecular Weight: 486.06
Associated Items:
Canonical SMILES: CC(C)C1=C[C@H]2OC3(CCC(NCCNc4cc(Cl)cc5cccnc45)CC3)OO[C@@]2(C)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O.O=C(O)CC(O)(CC(=O)O)C(=O)O
Standard InChI: InChI=1S/C27H36ClN3O3.2C6H8O7/c1-18(2)19-6-9-26(3)24(16-19)32-27(34-33-26)10-7-22(8-11-27)29-13-14-30-23-17-21(28)15-20-5-4-12-31-25(20)23;2*7-3(8)1-6(13,5(11)12)2-4(9)10/h4-5,12,15-18,22,24,29-30H,6-11,13-14H2,1-3H3;2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t22?,24-,26+,27?;;/m1../s1
Standard InChI Key: GIECMGIAJSBTCF-AFLGAMSHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 486.06 | Molecular Weight (Monoisotopic): 485.2445 | AlogP: 6.01 | #Rotatable Bonds: 6 |
Polar Surface Area: 64.64 | Molecular Species: BASE | HBA: 6 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 9.94 | CX LogP: 5.37 | CX LogD: 2.91 |
Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.30 | Np Likeness Score: 0.37 |
1. Sharma B, Singh P, Singh AK, Awasthi SK.. (2021) Advancement of chimeric hybrid drugs to cure malaria infection: An overview with special emphasis on endoperoxide pharmacophores., 219 [PMID:33989911] [10.1016/j.ejmech.2021.113408] |
Source(1):